You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Patent: 5,866,538


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,866,538
Title: Insulin preparations containing NaCl
Abstract:Insulin preparations of superior chemical stability, comprising human insulin or an analogue or derivative thereof, glycerol and/or mannitol, and 5 to 100 mM of a halogenide are disclosed.
Inventor(s): Norup; Elsebeth (Jyllinge, DK), Langkj.ae butted.r; Liselotte (Klampenborg, DK), Havelund; Svend (Bagsvaerd, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:08/879,991
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Claims and Patent Landscape of United States Patent 5,866,538

Introduction

United States Patent 5,866,538, though not specifically detailed in the provided sources, can be analyzed within the broader context of patent law, patent assertion entities, and the mechanisms for challenging patent validity. This analysis will delve into the key aspects of patent claims, the patent landscape, and the regulatory environment that shapes the enforcement and validity of patents like 5,866,538.

Understanding Patent Claims

Patent claims are the heart of any patent, defining the scope of the invention and what is protected. For a patent like 5,866,538, the claims must be clear, concise, and distinct to avoid issues such as obviousness-type double patenting or lack of patentable subject matter[2].

Patentable Subject Matter

The patent claims must be directed to eligible subject matter, avoiding laws of nature, natural phenomena, or abstract ideas unless they contain an "inventive concept" that transforms the nature of the claim[2]. This is crucial as the USPTO and courts strictly apply the Alice/Mayo test to determine patent eligibility.

Obviousness-Type Double Patenting

Patent applicants often face rejections due to obviousness-type double patenting, where claims in a later patent are deemed too similar to those in an earlier patent. To address this, applicants can use terminal disclaimers or reissue patents to ensure the validity of their claims[1].

The Patent Landscape

The patent landscape in the United States is complex and influenced by various factors, including legislative changes, judicial interpretations, and the activities of patent assertion entities.

Legislative Changes: The America Invents Act (AIA)

The AIA, enacted in 2011, significantly altered the patent landscape by introducing new administrative procedures such as inter partes review (IPR) and post-grant review (PGR). These procedures allow for the challenge of patent validity in an administrative forum, providing a faster and less expensive alternative to judicial proceedings[2].

Patent Trial and Appeal Board (PTAB)

The PTAB, established by the AIA, plays a critical role in reviewing patent applications and hearing challenges to patent validity. PTAB procedures are often preferred by accused infringers due to their speed, lower costs, and lower burden of proof compared to federal court litigation[2].

Patent Assertion Entities (PAEs)

PAEs, often referred to as "patent trolls," significantly impact the patent landscape. They can be categorized into two main types:

Portfolio PAEs

These entities negotiate licenses covering large portfolios of patents, often without first suing the alleged infringer. They generate substantial revenue through these licenses, with the FTC study indicating that they accounted for 80% of the reported revenue from PAE activities[3].

Litigation PAEs

Litigation PAEs focus on asserting patents through litigation, with a significant portion of their licenses following patent infringement suits. They are more aggressive in their assertion behavior compared to Portfolio PAEs[3].

Regulatory Environment and Proposed Rules

The USPTO has proposed several rules aimed at improving patent quality and reducing abusive practices.

Terminal Disclaimers and Continuation Applications

The USPTO's proposed rules link the enforceability of terminally disclaimed patents, discouraging the accumulation of questionable patents. This approach encourages brands to file continuations for patentably distinct inventions, ensuring that only innovative and high-quality patents are protected[1].

Restrictions on Claims and Continuation Applications

Proposed rules such as Rules 75, 78, and 114 aim to restrict the number of claims, limit continuation applications, and regulate the granting of requests for continuing examination. These rules are designed to improve patent quality and reduce the burden of poor-quality patents[1].

Impact on Innovation and Litigation

The current patent landscape and regulatory changes have significant implications for innovation and litigation.

Reducing Patent Troll Litigation

The creation of PTAB and the introduction of IPR and PGR have been aimed at reducing litigation by poor-quality patents and patent trolls. However, critics argue that these measures have created uncertainty in patent rights, potentially stifling innovation and discouraging investments in patent-intensive industries[2].

Balancing Patent Protection and Public Access

The regulatory environment must balance the need to protect innovative inventions with the need to ensure public access to new technologies. For example, in the pharmaceutical sector, terminal disclaimers can delay the entry of biosimilars and generics, affecting public health and access to affordable medications[1].

Case Study: Pharmaceutical Patents

The pharmaceutical industry provides a compelling example of the complexities in the patent landscape. Patents like those for IMBRUVICA, with multiple terminally disclaimed patents, highlight the issue of patent thickets and delayed access to biosimilars. This can result in higher costs for consumers and delayed access to life-saving medications[1].

Tools for Patent Analysis

To navigate the complex patent landscape, various tools are available for objective application review and analysis.

LexisNexis PatentOptimizer

Tools like LexisNexis PatentOptimizer automate the review process, helping to identify procedural objections, Section 112 rejections, and potential post-grant challenges. This ensures that patent applications are thoroughly reviewed, reducing the risk of costly mistakes and delays[5].

Key Takeaways

  • Clear and Distinct Claims: Patent claims must be clear, concise, and distinct to avoid rejections and challenges.
  • Administrative Challenges: IPR and PGR provide efficient mechanisms for challenging patent validity.
  • PAE Activities: PAEs significantly impact the patent landscape, with different business models affecting how patents are asserted.
  • Regulatory Changes: Proposed USPTO rules aim to improve patent quality and reduce abusive practices.
  • Balancing Protection and Access: The regulatory environment must balance patent protection with public access to new technologies.
  • Tools for Analysis: Automated tools can improve the patent review process, reducing risks and costs.

FAQs

What is the purpose of the Patent Trial and Appeal Board (PTAB)?

The PTAB was created to provide a more efficient system for challenging patents that should not have issued, improving patent quality and reducing unwarranted litigation costs[2].

How do terminal disclaimers affect patent enforceability?

Terminal disclaimers link the enforceability of related patents, discouraging the accumulation of questionable patents and ensuring that only innovative and high-quality patents are protected[1].

What are the differences between Portfolio PAEs and Litigation PAEs?

Portfolio PAEs negotiate licenses covering large portfolios without suing, while Litigation PAEs assert patents through litigation, often preceding licenses with patent infringement suits[3].

How do proposed USPTO rules impact continuation applications?

Proposed rules restrict the number of continuation applications and regulate the granting of requests for continuing examination to improve patent quality and reduce the burden of poor-quality patents[1].

What is the significance of the Alice/Mayo test in patent law?

The Alice/Mayo test determines whether patent claims are directed to eligible subject matter, ensuring that claims contain an "inventive concept" that transforms the nature of the claim[2].

Sources

  1. Letterhead DC Office - Regulations.gov: "Our patents reflect important innovative and inventive steps..."
  2. The Patent Trial and Appeal Board and Inter Partes Review: Congressional Research Service
  3. Patent Assertion Entity Activity: An FTC Study: Federal Trade Commission
  4. Aggregates of human insulin derivatives - Patent US-2002155994: PubChem
  5. Patent Analysis Tools for Objective Application Review - LexisNexis IP: LexisNexis IP

More… ↓

⤷  Subscribe

Details for Patent 5,866,538

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Novo Nordisk Inc. NOVOLOG insulin aspart Injection 020986 June 07, 2000 5,866,538 2016-06-20
Novo Nordisk Inc. NOVOLOG insulin aspart Injection 020986 January 19, 2001 5,866,538 2016-06-20
Novo Nordisk Inc. NOVOLOG insulin aspart Injection 020986 April 23, 2004 5,866,538 2016-06-20
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.